Abstract | PURPOSE: METHODS: A total of 17 patients who received Ozurdex injections in our institution as part of the GENEVA study were recalled for examination. Recorded parameters included final visual acuity (VA), final retinal thickness by optical coherence tomography, persistence of ME, and the occurrence of any complications. RESULTS: Mean follow-up time was 50.5 months. Patients with branch RVO (BRVO) had a more favorable prognosis than central RVO (CRVO), and their mean VA had improved significantly, whereas the mean VA for the patients with CRVO did not improve significantly. Retinal thickness had reduced significantly in the whole group and in each subgroup separately. Complications included 10 patients with cataract progression, 1 with elevated intraocular pressure, and 1 with neovascularization and vitreous hemorrhage. CONCLUSIONS: This is the first reported long-term evaluation of patients treated with Ozurdex. Our results indicate that it has favorable long-term safety profile, and may have a beneficial effect on the visual prognosis in BRVO even in the absence of continuous treatment. Further research is required to establish the optimal retreatment schedule for Ozurdex.
|
Authors | E Moisseiev, M Goldstein, M Waisbourd, A Barak, A Loewenstein |
Journal | Eye (London, England)
(Eye (Lond))
Vol. 27
Issue 1
Pg. 65-71
(Jan 2013)
ISSN: 1476-5454 [Electronic] England |
PMID | 23154502
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Inflammatory Agents
- Drug Implants
- Dexamethasone
|
Topics |
- Aged
- Aged, 80 and over
- Anti-Inflammatory Agents
(administration & dosage)
- Dexamethasone
(administration & dosage)
- Drug Implants
- Female
- Follow-Up Studies
- Humans
- Intravitreal Injections
- Macular Edema
(drug therapy, etiology)
- Male
- Middle Aged
- Prognosis
- Retinal Vein Occlusion
(complications)
- Visual Acuity
|